ArticleEuropean journal of nuclear medicine and molecular imaging2022
[
Article in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Performance of [European radiology · 2024Pooled it
- Fibroblast activation protein inhibitor-PET/CT in lung cancer: a prospective single-center study with histopathological correlation of fibroblast activation protein expression.International journal of clinical oncology · 2026Article
- Value of [European journal of nuclear medicine and molecular imaging · 2026Article
- Radiolabelled FAPI Radiotracers in Oncology: A Comprehensive Review of Current Diagnostic and Emerging Therapeutic Applications.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Diagnostic value of [Frontiers in oncology · 2026Article
- Article
- Radionuclide theranostics: advances and clinical applications in lung cancer.Frontiers in oncology · 2026Review
- Different detection rates of brain metastasis in different pathological types of lung cancer byBMC cancer · 2025Article
- Noninvasive diagnosis and classification of kidney transplantation rejection byEuropean journal of nuclear medicine and molecular imaging · 2025Article
- Fibroblast activation protein targeting radiopharmaceuticals: From drug design to clinical translation.Acta pharmaceutica Sinica. B · 2025Review
- [European journal of nuclear medicine and molecular imaging · 2025Article
- Relationship between PD-L1 expression and [European journal of nuclear medicine and molecular imaging · 2025Article
- Detecting radiation esophagitis usingBMC cancer · 2025Article
- Value of [European journal of nuclear medicine and molecular imaging · 2025Article
- Evaluating the diagnostic value ofJapanese journal of radiology · 2025Article
- [European journal of nuclear medicine and molecular imaging · 2025Article
- Comparison of the diagnostic accuracy betweenJournal of thoracic disease · 2025Article
- Article
- Exploring the value of FAP-targeted PET/CT in differentiating breast cancer molecular subtypes: a preliminary study.European journal of nuclear medicine and molecular imaging · 2024Article
- Clinical applications of fibroblast activation protein inhibitor positron emission tomography (FAPI-PET).Npj imaging · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
purposeHeterogeneity is found in the tumor microenvironment among different pathological types of tumors. Radionuclide-labeled fibroblast-activation-protein inhibitor (FAPI), as an important tracer for non-invasive imaging of the tumor microenvironment, can be used to evaluate the expression of FAP in cancer-associated fibroblasts, macrophages, and tumor cells. Our aim was to explore the ability of [
methodsWe prospectively enrolled 61 patients with histopathologically proven primary lung cancer with metastases. PET/CT scanning was performed before any antitumor therapy and 1 h after injection of 235.10 ± 3.89 MBq of [
resultsSixty-one patients with adenocarcinoma (ADC, n = 30), squamous cell carcinoma (SCC, n = 17), and small cell lung cancer (SCLC, n = 14) were enrolled in this study, and 61 primary tumors and 199 metastases were evaluated. No difference in [
conclusion[
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.